Table 1.

Association of clinical characteristics to neoadjuvant pCR by cohort

MAQCMDACCSS
HR+/HER2-negTriple-negativeHR+/HER2-negTriple-negative
CharacteristicNo.% pCRPNo.% pCRPNo.% pCRPNo.% pCRP
No. of patients1376.66835.316716.211130.6
Age, y1.0000.3090.6760.148
 <50626.53043.38814.86336.5
 >50756.73729.77917.74822.9
Tumor size at diagnosis (TNM)0.1390.6081.0000.064
 T0/T1/T2944.33839.58616.35040.0
 T3/T44311.62931.08116.06123.0
Lymph node1.0000.3040.8280.154
 Negative486.31118.26214.52842.9
 Positive896.75639.310517.18326.5
Modified Black's nuclear grade0.0060.1820.0030.542
 1–2902.21118.2847.11421.4
 34515.65042.07125.48231.7
 Unknown or indeterminate20.0714.31225.01533.3
PAM50 intrinsic subtype0.0500.0480.0161.000
 Luminal A525.80734.120.0
 Luminal B339.1425.04223.80
 HER2-enriched10.001118.2825.0
 Normal370.01513.31520.0944.4
 Basal1421.44942.92634.69230.4
LDHB (0.60 threshold)0.0270.0830.0010.359
 Low943.21816.712610.33122.6
 High4314.05042.04134.18033.8
LDHB (0.94 threshold)0.1170.0200.0060.087
 Low1064.72416.713411.94020.0
 High3112.94445.53333.37136.6

NOTE: P was calculated by Fisher exact test. For PAM50 intrinsic subtyping, basal-like subtype was compared with other subtypes pooled (luminal A, luminal B, HER2-enriched, and normal-like).